Multiple sclerosis

Alemtuzumab preserves neuroaxonal structure in MS

Alemtuzumab, the anti-CD52 monoclonal antibody used to treat relapsing–remitting MS (RRMS), appears to protect neuroaxonal structure compared to other first-line injectable treatments, a multinational study has found. The findings comes from a five year study that used optical coherence tomography (OCT) measures of neuroaxonal structure to compare the effects of alemtuzumab treatment in 24 RRMS ...

Already a member?

Login to keep reading.

© 2021 the limbic